Uploaded byOurania Koumi
Emerging trends in pharmaceutical industry 2012
1. The top 10 pharmaceutical companies by revenue in 2004 and 2011 are listed, with some companies changing ranks and Pfizer remaining the top company. 2. While the industry appears prosperous, the document notes that nothing could be further from the truth and asks the reader to find out why. 3. The pharmaceutical industry faces challenges from changes in the external environment including the economy, political structures, independent auditing bodies, payors, social factors, cultural forces, distributors, and technology. It also faces opportunities in specialty medicines, emerging economies, and customer-centric services.
More Related Content
Similar to Emerging trends in pharmaceutical industry 2012
Emerging trends in pharmaceutical industry 2012
- 1.
- 2. Top 10 PharmaRanking: Is this the whole picture? Rank Company 2004 Rank Company 2011 1 Pfizer 52,516 1 Pfizer 58,523 2 Bristol-Myers Squibb 47,348 2 Sanofi Aventis 40,310 3 GlaxoSmithKline 37,318 3 Merck & Co. 39,811 4 Sanofi-Aventis 31,615 4 Novartis 39,076 5 Novartis 28,247 5 GlaxoSmithKline 36,132 6 Hoffman-La Roche 25,163 6 Hoffman-La Roche 35,568 7 Merck & Co. 22,939 7 AstraZeneca 33,269 8 AstraZeneca 21,427 8 Johnson & Johnson 22,396 9 Abbott Laboratories 19,680 9 Lilly 21,050 10 Johnson & Johnson 19,380 10 Abbott Laboratories 19,894 It looks like the industry has not suffered from change. And business has never looked more prosperous. Nothing is further from the truth. Find out why. Sources: Med Ad News, 2004 Revenues http://www.contractpharma.com/issues/2007-07/view_features/2007-top-20-pharmaceutical-companies-report/, 2006, 2009; Scrip 100, Dec 2011 with 2010 Revenues in USD millions
- 3. A changing external environment. Canyou handle it? The Economy Political Structures Independent Payors Social /Legal Auditing Bodies Factors Framework The Suppliers Public Cultural Distributors / Health Professionals Demography Forces Dealers Technology
- 4. Opportunities. Specialty Medicines. Emerging Economies. Extentof pricing control. Customer-centric Services. Change in Target Audience. Challenges. Patent Expirees. New Business Models. Manage Corporate Reputation. It is about the Science. It should also be about the value you can bring to it.
- 5. How much Interestthe Issue Raises Pricing Corporate Reputation New Business Models Change Target Audience Customer-centric Services Patent Expiries Specialty Medicines Emerging Economies How fast Information on the Issue is Retrieved
- 6. Pharma Will Sellwhere Demand is higher: Where? PRB, US, 2008
- 7. Pharma Will Sellwhere Demand is higher: For What?
- 8. Pharma Will Sellwhere Demand is higher: Sales 2011
- 10. How well willPharma Sell? The R&D Crisis
- 11. How well willPharma Sell? Patent Erosion
- 12. How well willPharma Sell? Lack of New Compounds 2010
- 13. How well willPharma Sell? Decreasing New Compound Approvals
- 14. How well willPharma Sell? Pricing Pressures
- 15. How well willPharma Sell? Health System Reforms Worldwide Healthcare becomes more patient - centric Prescription Decision makers are many and varied Patients & Independent Auditing Bodies have an Increased
- 16. How well willPharma Sell? Technology on Steroids Connect. Measure. Add Value. http://www.imedicalapps.com, 2012
- 17. How well willPharma Sell? Ethics & Corporate Reputation
- 18. Heath Care isShaping up to the Needs Worldwide. How fit is Pharma to respond to growing medical needs?
- 19. Today we checkedthe weather and it’s plain sailing. Not for long.
- 20.